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Abstract
Background: The tumor suppressor p53 is an important regulator that controls various cellular networks, including cell
differentiation. Interestingly, some studies suggest that p53 facilitates cell differentiation, whereas others claim that it
suppresses differentiation. Therefore, it is critical to evaluate whether this inconsistency represents an authentic differential
p53 activity manifested in the various differentiation programs.
Methodology/Principal Findings: To clarify this important issue, we conducted a comparative study of several
mesenchymal differentiation programs. The effects of p53 knockdown or enhanced activity were analyzed in mouse and
human mesenchymal cells, representing various stages of several differentiation programs. We found that p53 down-
regulated the expression of master differentiation-inducing transcription factors, thereby inhibiting osteogenic, adipogenic
and smooth muscle differentiation of multiple mesenchymal cell types. In contrast, p53 is essential for skeletal muscle
differentiation and osteogenic re-programming of skeletal muscle committed cells.
Conclusions: These comparative studies suggest that, depending on the specific cell type and the specific differentiation
program, p53 may exert a positive or a negative effect, and thus can be referred as a ‘‘guardian of differentiation’’ at large.
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Introduction
The tumor suppressor p53 known as the ‘‘guardian of the
genome’’, plays a key role in prevention of cancer development
[1]. p53 is a sequence specific transcription factor that binds to
DNA and thereby activates specific transcription of target genes
[2,3] such as p21 [4]. Activation of p53 induces cellular programs
including cell cycle arrest, apoptosis or senescence which prevent
accumulation of genetically altered cells [5,6]. Moreover, p53 was
found to play a role in angiogenesis, invasion and motility,
glycolysis and autophagy [7,8,9,10,11]. These findings suggest that
p53 acts as an important general regulator that controls various
cellular gene networks [12].
Although the tumor suppressing activity of p53 has been clearly
established, less attention was given to its possible involvement in
the processes of cell differentiation and development. During
embryogenesis the transcription of p53 is tightly regulated
(reviewed in [13], yet initial analysis of p53 null mice failed to
detect any apparent developmental defects [14]. However, further
detailed studies revealed several abnormalities in at least some p53
null embryos. These included upper incisor fusion, ocular
abnormalities, polydactyly of the hindlimbs and exencephaly that
was exhibited by female embryos leading to a fatal phenotype [15].
p53 null adult males and females show reduced fertility due to
impaired spermatogenesis or embryonic implantation, respectively
[16,17,18]. In contrast to the apparent normal development of
most p53 null mice, with only sporadic developmental defects,
severe gastrulation defects have been observed in p53 deficient
Xenopus embryos [19]. One possible explanation for this
discrepancy could be the fact that in the mouse, the p53 family
members p63 and p73, which are expressed in early mouse
embryos may compensate for the loss of p53, resulting in the
incomplete penetrance of the developmental phenotype observed,
whereas in frogs p53 is solely responsible for early embryogenesis
[11]. In addition to the major role of p53 during Xenopus
development, recent studies in zebrafish demonstrate its function
in the control of proper gut and neuronal development [20,21].
Inhibiting p53 in the salamander prevents limb regeneration [22].
These findings demonstrate the essential role of p53 during various
differentiation processes of divergent organisms. The discovery
that lack of p53 in the mouse can lead to a fatal defect, clearly
implicates p53 as an important factor in development. The natural
selection of developmentally normal p53 null mice, in which
compensation by other p53 family members most likely masks
possible significant functions that p53 may play during differen-
tiation processes, and the influence of the specific mouse strain on
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with this in vivo model.
In vitro models and recent advances in gene knockdown
techniques enabled focusing on the specific function of p53 during
various differentiation programs. Indeed, a growing body of data
derived from in vitro models suggests that p53 plays a major
regulatory role in cell differentiation. Interestingly, however, it was
noticed that under some circumstances p53 facilitates cell
differentiation whereas in others, it seems to be suppressive
[23,24]. For example, introduction of wild-type (wt) p53 into
undifferentiated early pre-B cell line, which lacks p53 induced
their differentiation [25,26]. In addition, irradiation of another
pre-B cell line containing wt p53 induced differentiation, which
was inhibited by mutant p53, suggesting that radiation-induced
p53 activation was the differentiation inducer [27]. Induction
towards differentiation by addition of exogenous wt p53 and block
of normal differentiation pathways by addition of dominant
negative mutant versions of p53 was observed in several other cell
types as well, implying a positive role of p53 in these systems. The
latter include myoblasts, keratinocytes, oligodendrocytes, neurons
and thyroid cells [28]. However, recent studies demonstrated a
multifaceted function of p53 during specific differentiation
programs. These include mainly its involvement in osteogenic
differentiation. Hu ¨ttinger-Kirchhof et al. [29], showed that p53
deficiency leads to inhibition of osteogenesis, while others
demonstrated that it functions as a negative regulator of osteoblast
differentiation, skeletal development and bone remodeling
[30,31,32]. A major difference between these studies is the use
of cell systems, which imply a diverse role for p53 in a cell type
dependent manner. Similarly, while p53 was shown to be required
for differentiation of skeletal myogenic cells [33,34,35], a recent
study proposed that it is required for the tumor necrosis factor
alpha-mediated inhibition of myogenesis [36]. During adipogenic
differentiation of 3T3-L1 cells, p53 was shown to be downregu-
lated and to exhibit a reduction in its DNA binding activity,
suggesting its role as a negative regulator of adipogenesis [37,38].
p53 may also inhibit myofibroblasts differentiation, since its
inactivation in cancer associated fibroblasts is predicted to
contribute to their myofibroblast phenotype [39]. Notably, despite
extensive evidence regarding the involvement of p53 in diverse
differentiation processes, its role in myofibroblast and adipocyte
differentiation is still largely unknown.
Recent findings suggesting an inhibitory role for p53 in several
differentiation systems, which challenge the previous dogma,
claiming that p53 facilitates differentiation, prompted us to re-
evaluate its role in several well characterized in vitro cell
differentiation models. We have conducted a comparative study
of mouse and human mesenchymal cells, representing various
differentiation programs and evaluated the effect of either p53
knock-down or enhanced activity on their capacity to undergo a
specific cell differentiation program. Our data demonstrate that
p53 inhibits osteogenic, adipogenic and myofibroblast differenti-
ation of mesenchymal progenitor cells, while it is essential for
skeletal muscle differentiation and osteogenic re-programming of
skeletal muscle committed cells. At the molecular level, p53
downregulates the expression of the master differentiation-
inducing transcription factors myocardin (Myocd), Peroxisome
prolifirator-activated receptor c (PPARc) , and osterix. These
results disclose a new function of p53 during the differentiation of
adipocytes and myofibroblasts and further stress the versatile
nature of p53 function along various differentiation programs,
suggesting that its function is dependent on the context of the
specific cell fate. Our novel findings regarding p53 regulatory
function during adipogenesis suggest its possible influence on fatty
acid metabolism, which may affect energy production, obesity and
membrane synthesis.
Results
Mouse embryonic fibroblasts derived from p53 knockout
mice express elevated levels of defined groups of
differentiation markers
In order to obtain a general unbiased view of potential p53
involvement in various mesenchymal differentiation programs we
compared the expression of diverse differentiation markers in wild-
type (wt) mouse embryonic fibroblasts (MEFs) to those expressed
by p53 knockout (KO) MEFs. MEFs obtained from 13.5 dpc
embryos represent a heterogeneous population of primary
adherent cells with variable differentiation capacity. Due to the
potential heterogeneity of various MEFs preparations, we used
several independent isolate of MEFs derived from wt and p53 KO
embryos for quantitative real time RT-PCR (QRT-PCR) analysis.
We found that absolute expression levels of diverse differentiation
markers varied greatly between different MEF populations as well
as between different passages of the same culture. Therefore, for
the comparative analysis we used wt and p53 KO MEFs that were
obtained from sibling embryos and cultured for identical periods.
The absence of p53 expression and the concomitant downregu-
lation of p21 in the p53 KO MEFs studied were verified by
Western-blotting (Fig 1A). p53 KO MEFs consistently expressed
higher levels of several mesenchymal differentiation markers.
These included osterix and Runx2 of the osteogenic pathway
(Fig 1B), the key adipogenic transcription factors PPARc and
CCAAT/enhancer binding protein a (CEBPa) (Fig 1C), early
markers of skeletal muscle differentiation and cardiac transcription
factors (Fig 1D). The expression of Myocd, an important
myofibroblast/smooth muscle transcription factor, as well as that
of smooth muscle structural components, calponin (CNN1) and a-
smooth muscle actin (aSMA) were also higher in p53 KO MEFs
(Fig 1E). Collectively, these data revealed an intriguing picture of a
general upregulation of diverse mesenchymal differentiation
markers in p53 KO MEFs, which suggest an inhibitory role for
p53 in these differentiation pathways. Therefore, we decided to
test this hypothesis by focusing on defined stages of these
differentiation programs.
p53 inhibits osteogenic differentiation of mouse
mesenchymal progenitor cells
Previous data demonstrated a major regulatory role of p53 in
osteogenic differentiation in vitro and in skeletal development and
bone remodeling, in vivo [30,31]. These studies demonstrated a
negative regulatory role of p53 on two key osteogenic transcription
factors, Runx2 and osterix. In agreement with these results, we
observed elevated basal levels of these markers in p53 KO MEFs
(Fig 1B), which prompted us to investigate the role of p53 during
induction of this differentiation program. To this end, p53 KO
MEFs and their wt counterparts were treated with bone
morphogenetic protein 4 (BMP4), a known inducer of osteogenic
differentiation, and analyzed by QRT-PCR. As can be seen in
Figure 2A, the early osteogenic transcription factors, osterix and
Runx2 were induced to significantly higher levels in p53 KO
MEFs whereas induced levels of the terminal differentiation
marker, The levels of osteocalcin, a late osteogenic differentiation
marker were comparable in both MEFs types following BMP4
treatment. p53 KO MEFs exhibit also higher basal activity of the
osteogenic marker alkaline-phosphatase (ALP) compared to wt
MEFs. This enzymatic activity was further induced by BMP4
p53 Regulates Differentiation
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activity of proteins involved in osteogenesis.
As MEFs represent a heterogeneous population enriched with
variable levels of multipotent precursors, it is important to
determine whether the amplification observed is not a mere
reflection of an increase in the number of such precursors in the
p53 KO compared with the wt MEFs, or whether the cells exhibit
an authentic higher levels of differentiation markers and increased
differentiation capacity per cell. To this end we have knocked-
down the endogenous p53 in a given individual wt MEFs
population by infecting them with a retrovirus encoding for p53-
directed small hairpin RNA (sh-p53). p53 inactivation was
confirmed by both QRT-PCR and Western blot analysis
(Fig 2C). The basal and induced expression levels of osteogenic
differentiation markers of the MEFs pairs (sh-p53 and sh-control)
were measured. As shown in Fig 2D, both basal and induced levels
of osterix and Runx2 were upregulated in sh-p53 MEFs, while the
induced level of osteocalcin was comparable in these MEF pairs.
ALP activity was also elevated in sh-p53 compared to control
MEFs (not shown). Thus, inhibiting p53 in a given MEF
population, also results in increased levels of osteogenic differen-
tiation markers, similarly to p53 KO MEFs, which indicate that
p53 plays a specific regulatory role in osteogenic differentiation
program. Since we could not induce terminal differentiation of
MEFs in culture to typical osteoblasts, which give rise to Ca
2+
precipitates, we have used the multipotent bone marrow stromal
cell line, MBA-15, which can be induced to give rise to terminally
differentiated osteoblasts, and represent a clonal, homogenous cell
population [40]. First, we have knocked-down the expression of
p53 in these cells, by sh-RNA (Fig 3A). Inhibiting the expression of
p53 in MBA-15 cells resulted in elevated basal levels of both
osterix and osteocalcin (Fig 3B). Induction towards osteogenic
differentiation resulted in prominent Ca
2+ precipitate formation in
the MBA-15 sh-p53 cells compared to their controls, which
exhibited sparse precipitate formation (Fig. 3C). These results,
demonstrating a negative regulatory role of p53 on terminal
differentiation of bone marrow stromal cells further support
previous data showing a negative regulation of p53 during bone
formation, in vivo by using an in vitro model [30,31]. Thus, p53
negatively regulates key osteogenic transcription factors, resulting
in restrained osteogenic differentiation of both MEFs and bone-
marrow stromal cells, which correspond to two differentiation
stages; while MEFs represent an early stage, reflecting the process
of embryonic development, bone-marrow stromal cells are adult
Figure 1. MEFs derived from p53 KO mice exhibit elevated levels of various differentiation markers. (A) p53 wt and p53 KO MEFs were
subjected to Western blot analysis for p53 and p21. GAPDH serves as loading control. (B–E) Several isolations of MEFs derived from p53 KO or p53 wt
mice were grown in culture for several passages. Relative basal expression levels of osteogenic differentiation markers (B); adipogenic differentiation
markers (C); skeletal muscle and cardiogenic differentiation markers (D); and myofibroblast differentiation markers (E) were determined by QRT-PCR
analysis. The scale in (D) is logarithmic. Dots indicate fold expression in KO relative to wt MEFs. Each dot represents the comparison of single MEFs
pairs. The results are presented as a mean of two duplicate runs (N=2) after normalization to HPRT control. Statistical significance of the differences
between wt and KO MEFs was evaluated by paired one tailed Wilcoxon signed rank test and the p values for the genes are as follows: osterix
p,0.023; Runx2 p,0.031; PPARc p,0.004; CEBPa p,0.008; Pax3 p,0.001; Pax7 p,0.001; Myf5 p,0.001; Nkx2.5 p,0.001; Isl1 p,0.001; GATA4
p,0.001; GATA6 p,0.029; Myocd p,0.002; CNN1 p,0.012; aSMA p,0.039.
doi:10.1371/journal.pone.0003707.g001
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PLoS ONE | www.plosone.org 3 November 2008 | Volume 3 | Issue 11 | e3707Figure 2. p53 inhibits MEFs differentiation towards the osteogenic lineage. (A) p53 wt and p53 KO MEFs were grown in culture for 48 h,
then medium was changed to condition medium from 293T cells overexpressing BMP4 protein or to condition medium from control cells (NT). Total
RNA was isolated 48 hours later. Using QRT-PCR analysis, relative expression of osterix, Runx2 and osteocalcin were determined following BMP4
treatement. (B) Alkaline Phosphatase activity in the experiment described in (A) was measured 4 days following BMP4 treatment. (C–D) p53 wt MEFs
were infected with retrovirus encoding for either p53 directed sh-RNA (sh-p53) or control sh-RNA (sh-con). The relative expression level of p53 was
determined by QRT-PCR (C). Western blot analysis was performed for p53 and p21. GAPDH serves as a loading control. (D) A similar experiment as (A)
was performed in sh-p53 and sh-con MEFs. The results of QRT-PCR are presented as a range of two duplicate runs (N=2) after normalization to HPRT
control.
doi:10.1371/journal.pone.0003707.g002
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homeostasis.
p53 inhibits the adipogenic differentiation program
Our QRT-PCR analysis of multiple key differentiation markers
in the MEFs pairs demonstrate, for the first time, elevated
expression of the key adipogenic transcription factors PPARc and
CEBPa in p53 KO MEFs (Fig 1C). This suggests a negative
regulation of p53 during adipogenesis, which may implicate a
physiological role of p53 in fat metabolism. Therefore, we next
aimed at evaluating the role of p53 in adipogenesis. The
adipogenesis of MEFs by hormonal induction is a well-established
model system for the study of adipocyte differentiation in vitro [41].
In order to examine the potential of p53 KO and wt MEFs to
undergo adipogenic differentiation, these cells were treated with
insulin and dexamethasone, and subjected to QRT-PCR analysis
of various key adipogenic differentiation markers, at several time
points. PPARc is a transcription factor from the nuclear-receptor
superfamily that is both necessary and sufficient for adipogenesis
[42]. Consistent with its key role in adipocyte differentiation, the
majority of known adipogenic regulators function through control
of PPARc expression or activity. CEBPa is an additional
important factor in adipose tissue development [42]. Adipocyte
fatty-acid-binding protein, AP-2 (FABP4) and Adiponectin
(AdipoQ) are markers of differentiated adipocytes. Figure 4A
demonstrates that basal and induced levels of PPARc and CEBPa
were significantly higher in p53 KO MEFs. The levels of AP-2 and
AdipoQ markedly increased after induction. Importantly, Oil Red
O staining for typical lipid droplets revealed a spontaneous
adipocyte formation, even without hormonal induction, in p53
KO MEFs. Induction towards adipogenesis resulted in extensive
adipocyte differentiation of p53 KO but not of wt MEFs (Fig 4B).
In order to test whether lower levels of adipogenic differenti-
ation markers in wt MEFs represent a direct consequence of
Figure 3. p53 inhibits osteogenic differentiation in MBA-15 cells. (A) MBA-15 cells were infected with retroviruses encoding for either p53
directed sh-RNA (sh-p53) or control sh-RNA (sh-con). The relative expression level of p53 was determined by QRT-PCR (left panel). Western blot
analysis was performed for p53 and p21. GAPDH serves as a loading control (right panel). (B) Basal RNA expression levels for osterix and osteocalcin
were determined by QRT-PCR. The results of QRT-PCR are presented as a range of two duplicate runs (N=2) after normalization to HPRT control. (C)
MBA-15-sh-p53 and MBA-15-sh-con cells were subjected to induction of osteogenic differentiation by treatment with medium containing 50 mg/ml L-
ascorbic acid-2 phosphate, 10 Mm glycerol 2-phospate disodium salt and 10
28M dexamethasone (Induced) or with control medium (NT) for 6 days.
Osteogenic differentiation was detected by Alizarin Red staining for the detection of Ca
2+ precipitates.
doi:10.1371/journal.pone.0003707.g003
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PLoS ONE | www.plosone.org 5 November 2008 | Volume 3 | Issue 11 | e3707Figure 4. p53 inhibits the adipogenic differentiation program in MEFs. (A–B) Confluent cultures of p53 wt and p53 KO MEFs subjected to
induction of adipogenic differentiation by treatment with medium containing 10 mg/ml insulin, 10
26M dexamethasone, 0.5 mM 3-Isobutyl-1-
methylxanthine (Adipogenic medium) or with control medium (NT). The cells were grown for three weeks with medium replacement once in three
days. Total RNA was isolated before the induction of differentiation (0d) as well as 7 and 21 days later. Relative expression of PPARc, CEBPa, Ap2 and
AdipoQ were determined by QRT-PCR analysis (A). Adipogenic differentiation was assessed using Oil Red O staining for lipid droplets (B). (C–D) p53
wt and p53 KO MEFs were grown in culture for 48 hours, then treated with Nutlin-3 at a final concentration of 25 mM, for 24 hours (Nutlin) or left
p53 Regulates Differentiation
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Nutlin-3, a small molecule inhibitor of the murine double minute
(MDM2) gene [43]. Treatment of cells with this drug resulted in
accumulation of p53 and activation of its downregulation target,
p21 (Fig 4C). As demonstrated in Figure 4D, Nutlin-3 treatment
resulted in a p53-dependent downregulation of PPARc.
To verify that the effect of p53 deficiency on adipogenic
differentiation is not a result of the heterogeneous nature of the
MEFs population, we repeated these experiments using the sh-p53
and control MEFs described above. Similarly to p53 KO MEFs,
the sh-p53 MEFs exhibited enhanced levels of the key adipogenic
markers, and extensive mature adipocyte formation upon
induction (Fig 4E, F).
We have repeated these experiments, using the multipotent
MBA-15 cell line. While basal levels of PPARc and AP-2 were not
changedin sh-p53MBA-15,compared to their control counterparts
(the levels of CEBPa were even lower in sh-p53 cells), induced levels
of PPARc, adiponectin and AP-2 were elevated in sh-p53 MBA-15
compared to control cells (Suppl. Fig. S1a). Moreover, when these
cells were induced to differentiate, prominent adipocyte colonies
appeared only in the sh-p53 cells (Suppl. Fig. S1b).
As mentioned above, PPARc is a major adipogenic factor.
Activation of this nuclear receptor by ligands results in transcrip-
tional activation of numerous factors participating in adipogenesis.
Therefore, it is plausible to assume that p53 may regulate also
downstream molecules of the adipogenic program, and exert its
inhibitory effect not only through the regulation of PPARc but
through other downstream effectors as well. Indeed, as demonstrat-
ed in Figure 4A, the levels of CEBPa were higher in sh-p53 MEFs,
both at basal and induced conditions. To determine whether
facilitation of adipogenic differentiation in the absence of p53 is
PPARc-dependent, we used the irreversible PPARc antagonist,
GW9662. This compound was shown to prevent PPARc activation
by covalently modifying a cysteine residue in its ligand binding site.
[44]. As shown in Figure 4G, addition of GW9662 to the induction
medium of sh-p53 MEFs resulted in complete inhibition of
adipocyte differentiation, suggesting that upregulation of other
important adipogenic transcription factors such as CEBPa, in p53-
deficient cells cannot compensate PPARc inhibition.
Taken together, our results demonstrate that p53 inhibits
adipogenic differentiation in two mesenchymal stem cells popu-
lations, representing different stages, as mentioned above. Given
the established key role of PPARc and CEBPa transcription
factors in adipogenesis, their transcriptional repression by p53 is
likely to contribute to the observed inhibitory effect of p53 on
adipogenic differentiation. Of note, these results imply a regulatory
role of p53 in the process of fat accumulation, consequently
controlling the major metabolic energy source.
p53 negatively regulates myofibroblast/smooth muscle
differentiation by inhibiting the expression of Myocd
p53 KO MEFs exhibited higher levels of smooth muscle
differentiation markers (Fig 1E). However, we were not able to
induce myofibroblast/smooth muscle differentiation program in
MEFs. Thus, in order to study the role of p53 during smooth
muscle differentiation, we used the hTERT immortalized human
embryonic lung fibroblasts, WI-38, which can undergo myofibro-
blasts/smooth muscle differentiation, expressing smooth muscle
proteins [45]. The specific role of p53 in myofibroblast
differentiation is still unclear. In order to evaluate its role along
this differentiation pathway, we knocked-down p53 expression in
early passaged hTERT-immortalized WI-38 cells [46] by infecting
them with a retrovirus encoding for human p53-directed sh-RNA.
Introduction of sh-p53 resulted in a significant decrease in basal
p53 protein levels as compared to cells infected with control
shRNA (Fig 5A). As expected, p53 knock-down resulted in down-
regulation of its transcriptional target, p21/waf1, both at the
mRNA and protein levels (Fig 5A). In order to characterize the
role of p53 in myofibroblast differentiation, WI-38 sh-p53 cells and
their controls were treated with transforming growth factor b
(TGFb), an inducer of myofibroblast differentiation, and analyzed
for the induction of several differentiation markers. In agreement
with our previous study [45], we found that TGFb treatment
induced myofibroblast differentiation. Importantly, the induction
of myofibroblast differentiation markers such as aSMA, CNN1
and smooth muscle-myosin heavy chain (SM-MHC), following
24 hr of TGFb treatment, was facilitated in the sh-p53 expressing
cells compared with their controls (Fig 5B). Western blot analysis
revealed a dramatic upregulation of SM-MHC protein levels in
WI-38 sh-p53 cells (Fig 5C). Collectively, these results imply that
basal p53 activity negatively regulates TGFb-induced myofibro-
blast differentiation of human fibroblasts.
To further substantiate the inhibitory role of p53 in myofibro-
blast differentiation, we used an additional method of p53
inactivation, namely, a dominant negative p53 peptide GSE56
[47]. Following TGFb treatment WI-38 cells stably expressing
GSE56 also exhibit augmented induction of myofibroblast
differentiation markers compared with WI-38 control cells. This
was evident by QRT-PCR analysis (Sup. Fig. S2).
In our previous studies we demonstrated that Myocd, known as
an important transcriptional regulator of smooth and cardiac
muscle development, plays a key role in myofibroblast differen-
tiation of WI-38 cells [45,48]. As shown in Figure 6A, treatment of
hTERT-immortalized WI-38 cells with TGFb resulted in a robust
induction of Myocd mRNA, reaching a peak at 6 hr of treatment.
Notably, the induced levels of Myocd mRNA were significantly
higher in the sh-p53 expressing cells compared to their controls. As
an additional approach to test the effect of p53 on Myocd mRNA
expression we used Nutlin-3. Treatment of cells with this drug
resulted in accumulation of p53 and activation of its downstream
target, p21 as well as in a p53-dependent downregulation of
Myocd mRNA (Fig 6B). Since p53 KO MEFs express higher levels
of Myocd than wt MEFs (Fig 1E), we analyzed whether induction
of p53 in MEFs, following Nutlin treatment, will result in
repression of Myocd also in this cell type. As evidenced in
Figure 6C, this treatment resulted in ,2.5-fold repression of
Myocd mRNA in p53-proficient cells, whereas only about 30%
reduction was observed in p53 KO MEFs. Thus, similarly to the
situation in human embryonic fibroblasts, p53 represses mRNA
levels of Myocd in MEFs.
In order to test whether p53-mediated downregulation of
Myocd mRNA results from transcriptional repression of its
promoter by p53, a 1.0-kb DNA fragment upstream of the
transcription start site of human Myocd gene was fused to
untreated (Control). Western blot analysis was performed for p53 and p21.GAPDH serves as a loading control (C). Relative expression of PPARc was
determined by QRT-PCR. Normalized expression levels in control samples were set to 100% (D). (E–F) A similar experiment as A–B was performed in
sh-p53 and sh-con MEFs. The results of QRT-PCR are presented as a range of two duplicate runs (N=2) after normalization to HPRT control. (G) MEFs-
sh-p53 cells were induced with adiogenic medium either in the presence of the PPARc inhibitor GW9662, or without it. Adipogenic differentiation
was assessed using Oil Red O staining for lipid droplets.
doi:10.1371/journal.pone.0003707.g004
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null Saos-2 cells that express high endogenous levels of Myocd. As
shown in Figure 6D, co-transfection of Myocd promoter reporter
construct with increasing doses of wt-p53 resulted in a dose-
dependent repression of the reporter activity.
Taken together, our results demonstrate that p53 downregulates
Myocd both in human and murine fibroblasts. This effect is likely
mediated through repression of the Myocd promoter.
p53 positively regulates both myogenic and osteogenic
differentiation of skeletal muscle committed cells
As demonstrated in Fig 1D, p53 KO MEFs express extreme
levels of the skeletal muscle transcription factors, Pax3, Pax7 and
Myf5, which represent early stages of skeletal muscle differenti-
ation. Since the levels of late differentiation markers of skeletal
myogenesis (e.g. myogenin and Myosin heavy chain) were not
elevated even upon induction of MEFs towards the skeletal muscle
lineage using horse serum and insulin, we adopted the skeletal
muscle committed cell-line C2 [49] as the most suitable in vitro
system to study the role of p53 during myogenesis. Most of
previously published data suggest a positive role of p53 during
skeletal muscle differentiation [33,34,35]. It was also suggested
that the loss of p53 may be compensated by p63 and p73, the
other p53 family members, and a dramatic inhibition of skeletal
myogenesis is achieved when all 3 members are inactivated [33].
We first knocked-down p53 in C2 cells, by sh-RNA and verified
the lack of its expression (Fig 7A). Comparative analysis of the
various skeletal muscle differentiation markers between C2-sh-p53
Figure 5. p53 negatively regulates myofibroblast/smooth muscle differentiation program. (A) h-TERT immortalized, early passaged WI-38
cells were infected with retroviruses encoding for either p53 directed sh-RNA (sh-p53) or control sh-RNA (sh-con). Relative expression levels of p53
(left panel) and p21 (middle panel) were determined by QRT-PCR, or by Western blot analysis (right panel). GAPDH serves as a loading control. (B–C)
WI-38-sh-p53 and WI-38-sh-con cells were grown in culture for 48 hours (non treated, NT); serum starved for 24 hours, and then treated with a fresh
serum-free medium with 1 ng/ml TGFb for 24 h. Relative expression of aSMA, CNN1 and SM-MHC was determined by QRT-PCR (B). Equal amounts of
total protein were subjected to Western blot analysis for SM-MHC. GAPDH serves as loading control (C). The results of QRT-PCR are presented as a
range of two duplicate runs (N=2) after normalization to GAPDH control.
doi:10.1371/journal.pone.0003707.g005
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early markers. However, when the cells were induced to
differentiate by media containing horse serum and insulin,
markers that are expressed at later stages were markedly reduced
in C2-sh-p53 cells compared to C2-sh-control cells (Fig 7B). These
changes were in agreement with a dramatic decrease in the
differentiation capacity of C2-sh-p53 compared to C2-sh-control
cells, as reflected by the formation of multinucleated fibers, and the
expression of myosin heavy chain in the fibers (Fig 7C).
BMP4/2 induces re-programming of myogenic cells to
osteoblasts. It was previously shown that inhibition of all three
p53 family members can inhibit this osteogenic differentiation of
myogenic cells [33]. Due to the results demonstrating an inhibitory
role of p53 in osteogenic differentiation of mesenchymal stem cells
(Figs. 2, 3), we decided to analyze the effect of p53 deficiency on
osteogenic differentiation of C2 cells. Surprisingly, in contrast to
the negative regulatory role of p53 during osteogenic differenti-
ation of MEFs and MBA-15 cells, p53 was found essential for both
expression of osteogenic markers, and osteogenic differentiation of
C2 cells (Fig 7D,E). Thus, in contrast to the inhibitory role of p53
in mesenchymal stem cells differentiation, p53 plays a positive
regulatory role during the differentiation of muscle committed
cells, both towards myogenesis and osteogenesis. Thereby, it can
either induce or inhibit the expression of identical genes,
depending on the specific cellular fate.
Discussion
Cell differentiation represents a heterogeneous process which
seems to involve various gene networks, some of which are unique
to an individual differentiation program and others can be shared.
By adapting a comparative study of several differentiation
programs we found that p53 can play opposing roles during these
programs, in a cell fate dependent manner.
Enhanced proliferation and a differentiation block are consid-
ered to be steps preceding cell transformation and tumor
formation. Consequently, this agrees with the notion that p53, a
tumor suppressor gene, will facilitate differentiation which is
associated with cell growth arrest. Therefore, the recent data
demonstrating an inhibitory role of p53 during osteogenesis of
several in vitro and in vivo models warrant further assessment
regarding p53 activity during normal physiological processes of
Figure 6. p53 downregulates Myocd expression. (A) h-TERT immortalized, early passaged WI-38-sh-p53 and control cells were grown in culture
for 48 hours (non treated, NT); serum starved for 24 hours (Starv.), and then treated with a fresh serum-free medium with 1 ng/ml TGFb for the
indicated time periods. Relative expression of Myocd was determined by QRT-PCR. The results of QRT-PCR are presented as a range of two duplicate
runs (N=2) after normalization to GAPDH control. (B) h-TERT immortalized, early passaged WI-38-sh-p53 and control cells were treated with Nutlin-3
at a final concentration of 25 mM for 24 hours (Nutlin) or left untreated (Control). Western blot analysis was performed for p53 and p21.GAPDH serves
as a loading control (left panel). Relative expression of Myocd was determined by QRT-PCR. Normalized expression levels in control samples were set
to 100% (right panel). The results of QRT-PCR are presented as a range of two duplicate runs (N=2) after normalization to GAPDH control. (C) p53 wt
and p53 KO MEFs were grown in culture for 48 hours, then treated with Nutlin-3 at a final concentration of 25 mM for 24 hours (Nutlin) or left
untreated (Control). Relative expression of Myocd was determined by QRT-PCR. Normalized expression levels in control samples were set to 100%.
The results of QRT-PCR are presented as a mean6SD of two duplicate runs after normalization to HPRT control. (D) Saos-2 cells were transiently co-
transfected with 300 ng Myocd promoter-luciferase reporter and the indicated amounts of wild type p53 expression plasmid. Reporter activity was
determined 48 hours later. Transfection efficiency was normalized on the basis of the activity of the co-transfected renilla luciferase.
doi:10.1371/journal.pone.0003707.g006
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PLoS ONE | www.plosone.org 9 November 2008 | Volume 3 | Issue 11 | e3707Figure 7. p53 positively regulates both myogenic and osteogenic differentiation of skeletal muscle cells. (A) C2 cells were infected with
retroviruses encoding for either p53 directed sh-RNA (sh-p53) or control sh-RNA (sh-con). The relative expression level of p53 was determined by
QRT-PCR (left panel). Western blot analysis was performed for p53 and p21. GAPDH serves as a loading control (right panel). (B–C) C2-sh-p53 and C2-
sh-con cells were grown in culture for 48 hours and then subjected to induction of myogenic differentiation by treatment with medium containing
10% horse serum and 100 ng/ml insulin (10HI), or with control medium (non treated, NT) for 48 hours. Relative expression levels of Myf5, MyoD,
Myogenin, and Myl4 were determined by QRT-PCR analysis (B).Myogenic differentiation was assessed using Giemsa stain and immunostaining for
MHC (C). (D) C2-sh-p53 and C2-sh-con cells were grown in culture for 48 h, then medium was changed to condition medium from 293T cells
overexpressing BMP4 protein or to condition medium from control cells (non treated, NT). Total RNA was isolated 48 hours later. Relative expression
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PLoS ONE | www.plosone.org 10 November 2008 | Volume 3 | Issue 11 | e3707cell growth and differentiation. Here we demonstrate that p53
inhibits not only osteogenesis as already shown before in other
experimental systems, but also serve as an inhibitor of adipogenesis
and myofibroblast differentiation of both human and mouse
fibroblasts, and of mouse bone marrow stromal cells. In contrast to
this broad inhibitory activity, p53 is required for differentiation of
skeletal muscle cells towards mature myofibers or osteoblasts.
The involvement of p53 in osteogenesis was recently reported
by several groups. Two independent studies have addressed the
role of p53 in mouse differentiation models and have established
that p53 functions as a negative regulator of osteoblast
differentiation in-vivo and in-vitro (reviewed in [24]. Both groups
show that p53 suppresses osteoblast differentiation by repressing
the expression of key osteogenic transcription factors, Runx2 or
osterix. Furthermore, an additional in-vitro study provided
evidence that the absence of p53 promotes osteogenesis in
mesenchymal stem cells [32]. In agreement with these findings
we show, that knockdown of p53 in MEFs results in elevated
expression of osterix and Runx2, as well as in higher basal and
BMP4 induced ALP activity. Moreover, we present evidence that
downregulation of p53 in the multipotent bone-marrow stromal
cells, MBA-15, results in significant induction of their ability to
undergo terminal osteogenic differentiation and form Ca
2+
precipitates. Thus, p53 negatively regulates osteogenic differention
in MEFs and bone-marrow stromal cells. While MEFs represent
an early stage, reflecting the process of embryonic development,
bone-marrow stromal cells are adult progenitor cells, which
maintain proper bone differentiation and homeostasis.
In addition to the inhibitory role of p53 during osteogenesis,
using the same cell types (primary MEFs and MBA-15) we provide
compelling evidence that p53 inhibits adipogenesis in vitro. Our
findings that p53 represses expression of the key adipogenic
transcription factors PPARc and CEBPa might represent a
mechanistic basis for this effect. Although PPARc plays a central
role, as both necessary and sufficient factor during adipogenesis,
there are more than one hundred other transcription factors that
are expressed in adipocytes [42]. Therefore, the fact that the
PPARc antagonist, GW9662, completely blocked the accelerated
adipogenic differentiation of sh-p53 MEFs (Fig. 4G), suggests that
p53 might exert its inhibitory effect through this upstream key
regulator of adipocyte differentiation.
In addition to its function as a regulator of adipocytes
differentiation, PPARc is expressed by several other tissues, and
is involved in a number of pathological processes, such as
inflammation and cancer [50]. It was found to be highly expressed
by normal colonic mucosa, colorectal adenocarcinomas, and colon
cancer cell lines [51,52,53]. Mice treated with a PPARc ligand
have greater number of polyps in the colon [54], and the levels of
PPARc mRNA in tumors of colorectal cancer patients were higher
than those in adjacent normal colonic mucosa [55]. We observed
upregulation of PPARc mRNA in the colon of part of p53 null
mice compared to their wt littermates (data not shown). Due to the
incomplete penetrance of the p53 null phenotype, a larger group
of mice should be tested to verify the specific effect of p53
deficiency on PPARc expression, in vivo. Thus, while the lack of
p53 in cells that can give rise to adipocytes leads to their terminal
adipogenic differentiation, p53 deficiency that may lead to
upregulation of PPARc expression in colonic epithelial cells could
result in their neoplastic transformation. This suggests a complex
and/or indirect mechanism linking p53 and PPARc.
Osteoblasts and adipocytes are derived from multipotent
marrow mesenchymal cells, which express low levels of both
adipogenic and osteogenic factors. Factors of one lineage repress
factors of the other lineage, thereby maintaining the undifferen-
tiated state of these cells. Commitment of marrow mesenchymal
cells towards one of these lineages occurs when this balance is
tipped leading to activation of lineage-specific transcription factors
that promotes one cell fate, while repressing the other [42]. Thus,
through its regulation on key osteogenic and adipogenic
transcription factors, p53 may function to maintain this delicate
balance, and the undifferentiated state of these stem cells, while
p53 deficiency may unleash the controlled regulation of the
multipotential stem state of these cells, enabling their enhanced
differentiation towards both directions.
Several lines of evidence support the predicted inhibiting role of
p53 in adipogenesis also in vivo. The physiologic role of p53 in fat
metabolism is supported by the fact that p53 and its target genes are
highly induced in adipocytes of the genetically obese, ob/ob mice in
a fed state, leading to negative regulation of several lipogenic genes,
while disruption of p53 in these mice partially restored their
expression. Thus, the activation of p53 might constitute a negative
feedback loop against excess fat accumulation in adipocytes [56]. In
addition, mice over-expressing an active p53, exhibit reduced mean
thickness of subcutaneous adipose layer [57].
Most of the fat that is stored in adipocytes serves mainly for
energy production, since it is oxidized for the generation of ATP to
drive metabolic processes. Thus, our data suggest that p53 may
control the major metabolic energy source, by regulating the
accumulation of fat storage. The role of p53 in energy metabolism
was recently demonstrated [9]. The fact that p53 deficiency shifts
the balance towards glycolysis rather than oxidative phosphory-
lation [58] means that more acetyl-CoA molecules serve as
precursors for fatty acid synthesis, instead of being oxidized. Thus,
p53 deficiency not only results in upregulation of key adipogenic
transcription factors, but may also affect the increased production
of fatty acids that are stored in fat droplets of adipocytes. It will be
interesting to analyze fatty acids metabolism, in vivo, in p53 KO
versus wt mice that were fed with a high fat diet.
The differentiation of smooth muscle is a readily reversible
process in which myofibroblasts represent an intermediate stage in
the phenotypic spectrum that exists between fibroblasts and
smooth-muscle cells. Our results demonstrate that p53 plays an
inhibitory role in this differentiation pathway. Accordingly,
inactivation of p53 in cancer associated fibroblasts is predicted
to contribute to their myofibroblast phenotype. Such stromal
myofibroblasts, present in invasive human breast carcinomas were
demonstrated to promote tumor growth and angiogenesis through
elevated SDF-1/CXCL12 secretion [39]. In addition, high-grade
sarcomas that form in mice following conditional mutation of K-
Ras and p53 expressed markers of myofibroblastic differentiation
[59]. Although the authors did not observe differences in
immunohistochemical staining according to the different p53
genotypes, it would be interesting to assess the influence of p53
status on the extent of myofibroblast markers expression in this
model using more quantitative methods such as RT-PCR or
Western blotting..
levels for osterix and osteocalcin were determined by QRT-PCR. The results of QRT-PCR are presented as a range of two duplicate runs (N=2) after
normalization to HPRT control. (E) C2-sh-p53 and C2-sh-con cells were grown in culture for 48 h, then medium was changed to condition medium
from 293T cells overexpressing BMP4 protein. Osteogenic differentiation was assessed by measuring ALP activity and Alizarin Red staining for Ca
2+
precipitates.
doi:10.1371/journal.pone.0003707.g007
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we found significantly higher levels of the early markers of
myogenic differentiation, Pax3, Pax7 and Myf5, in p53 KO
MEFs, we failed to detect terminal differentiation towards mature
skeletal muscles upon appropriate stimuli (data not shown). We
also found that p53 inactivation attenuates expression of terminal
markers of muscle differentiation in C2 myoblasts following
differentiation induction. These results are in agreement with
those of Cam and coworkers, who demonstrated that p53 plays a
positive role at late stages of myogenic differentiation through
transactivation of the Rb gene [33]. It was previously demon-
strated that inhibition of all the p53 family members (p53, p63,
and p73) inhibit skeletal myoblasts reprogramming to osteoblasts
[33]. Here we demonstrate for the first time that p53 deficiency by
itself is sufficient for this inhibition (Fig 7D,E). While osterix
expression was upregulated in sh-p53 MEFs and MBA-15 cells,
p53 deficiency led to inhibition of osterix expression in skeletal
myoblasts. Thus, p53 may exert opposing effects along the same
differentiation program occurring within different cell types.
Our data demonstrating opposing effects of p53 in different cell
types may hold several possible explanations. One explanation
could be that the function of p53 is dependent on distinct stages of
mesencymal/mesodermal differentiation. We demonstrate that
p53 suppresses mRNA levels of transcription factors, important at
the early stages of differentiation like Myf5 and Pax3. We also
confirm the results of others showing that p53 leads to repression
of the osteogenic transcriptional regulators osterix and Runx2
[30,31]. In contrast, p53 has differentiation-promoting role at late
stages of several differentiation programs. For example, the early
and intermediate osteogenic markers, Runx2 and osteopontin,
were upregulated in p532/2 mesenchymal stem cells (MSCs)
compared with wt cells during osteogenesis. However, the terminal
osteogenic marker gene osteocalcin was lower in p532/2 MSCs,
indicating impaired terminal differentiation [32]. Besides the
transcriptional repression of transcription factors that function at
early phases of differentiation programs, an additional possible
explanation for the observed dichotomy of p53 function at
different stages of differentiation relates to its known cell cycle
inhibitory effect. Whereas early stages of differentiation are often
executed concomitantly with proliferation, cell cycle arrest is
associated with terminal differentiation in several mesenchymal
differentiation programs. Absence of p53 facilitates cycling of
MSCs but blocks subsequent terminal differentiation leading to
accumulation of early and intermediate progenitors. This is
reflected in the differentiation of skeletal myoblasts, where p53
may inhibit the expression of early transcription factors, but is
required for cell cycle exit and terminal differentiation of these
cells ([33] Fig. 1D, Fig. 7). The relationship between cell cycle
inhibitory effect of p53 and its regulatory effects on the expression
of master early differentiation transcription factors remains to be
determined. It should be born in mind that differentiation and cell
cycling are interconnected pathways, and thus it is expected that
p53, shown to be involved in both, is a key factor in coordinating
these pathways.
This study suggests that p53 acts as a general regulator in cell
differentiation. While in some differentiation programs p53
facilitates the process, in others it exerts suppression. In agreement
with previously published data we found that p53 accelerated
differentiation of skeletal muscle cells. Interestingly, we observed
that p53 attenuated adipogenic cell differentiation, as well as
myofibroblast/smooth muscle differentiation. In the case of
osteogenesis, p53 plays a dichotomic function which is cell fate
dependent. We observed that while p53 attenuates osteogenic
differentiation of mesenchymal precursors (in agreement with
previous reports [30,31,32]), it facilitates osteogenic differentiation
of myogenic committed cells (Fig 8). This suggests that p53 plays a
complex role in regulation of cell differentiation at large. Thus,
p53 can be considered as a ‘‘guardian of differentiation’’
maintaining the fine balance between mutual key regulatory
events during mesenchymal cell differentiation.
Methods
Experimental Procedures
Cell culture and differentiation induction
Primary mouse embryonic fibroblasts (MEFs) were derived from
p53 wt and p53 KO sibling embryos, and maintained with
DMEM supplemented with 10% fetal calf serum (FCS) and
antibiotics. The amphotropic and ecotropic Phoenix retrovirus-
producing cells were from the American Type Culture Collection
(Rockville, MD). The immortalized primary human embryonic
lung fibroblasts (WI-38) were generated as previously described
[60], and cultured in MEM supplemented with 10% FCS, 1 mM
sodium pyruvate, 2 mM L-glutamine, and antibiotics. The
marrow stromal cells MBA-15 [40], and the 293T cells expressing
BMP-4 were maintained in DMEM supplemented with 10% FCS
and antibiotics. C2 cells [549] were cultured in DMEM
supplemented with 20% FCS and antibiotics.
For induction to myofibroblasts, 6610
5 WI-38 cells were seeded
in 10 cm plates 2 days before starvation initiation. When
starvation is indicated, cells were washed twice with PBS and
changed to serum-free medium for 24 hr. Cells were exposed to
1 ng/ml TGFb-1 (R&D Systems, Abingdon, UK) for the indicated
time periods. For osteogenesis, MEFs were grown for a few days
until subconfluence, then medium was changed to conditioned
medium from 293T cells that secrete BMP-4 for the indicated time
points. Alkaline Phospatase activity was detected as described [61].
For myogenesis, subconfluent C2 cells were cultured in 10HI
medium (DMEM containing 10% horse serum and 0.04 units/ml
Figure 8. A model depicting p53 as a regulator of mesenchy-
mal cell differentiation. p53 regulates differentiation of mesenchy-
mal cells in a dichotomic fashion. In case of differentiation of
mesenchymal precursors (MEFs, WI-38 and MBA-15), p53 attenuates
myofibroblast/smooth muscle, adipogenic and osteogenic cell differ-
entiation. In contrast, in case of more committed cells (C2), it facilitates
their differentiation towards both the myogenic and osteogenic
lineages.
doi:10.1371/journal.pone.0003707.g008
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with Giemsa, or fixed with 4% paraformaldehyde for 10 min, and
immunostainned with anti-Myosin Heavy Chain (Clone MF-20,
Hybridoma bank), as described [62]. For adipogenesis, cells were
plated at a high density to reach confluence. The next day the
medium was changed either to a fresh control medium or to
adipogenic medium containing 10 mg/ml insulin, 10
26M dexa-
methasone, 0.5 mM 3-Isobutyl-1-methylxanthine (all from Sigma,
IL). The cells were maintained for three weeks with medium
replacement twice a week. Adipogenesis was detected by Oil red O
staining. The PPARc antagonist, GW9662 (Alexis Biochemicals),
was added to the adipogenic differentiation medium at a
concentration of 0.5 mM. Cells were fixed and stained with Oil
red O after 14d. For Osteogenesis, MBA-15 cells were plated at a
high density so to reach confluence. The medium was changed the
next day either to a fresh control or to osteogenic medium,
containing 50 mg/ml L-ascorbic acid-2 phosphate, 10 mM
glycerol 2-phospate disodium salt and 10
28M dexamethasone
(all from Sigma, IL). Osteogenic differentiation was detected by
Alizarin Red staining as described [63]. For Nutlin-3 treatment,
subconfluent cell cultures were treated with Nutlin-3 (Alexis
Corporation, San Diego, CA) at a final concentration of 25 mM
for 24 hours. Stock solution was prepared as 10 mM in DMSO.
Retroviral Constructs and infections
pBabe-hTERT-puro was kindly provided by Dr. JW. Shay
(University of Texas Southwestern Medical Center, Dallas, Texas,
USA). For human p53 knockdown, the p53 short hairpin RNA
(shRNA) vector, pWZL-shp53-blast and its mouse NOXA shRNA
control vector, pWZL-shNOXA-blast were obtained by subclon-
ing the p53 and NOXA fragments from pBabe-shp53- puro and
pBabe-shNOXA-puro, correspondingly, which were kindly pro-
vided by Dr. D. Ginsburg (Bar-Ilan University, Ramat Gan,
Israel). PLXSN-GSE56-neo was obtained from subcloning GSE56
BamH1fragment from pBabe-GSE56-puro which was kindly
provided by Dr.AW Gudkov (Roswell Park Cancer Institute,
Buffalo, NY, USA) into pLXSN.
For mouse p53 knockdown, the p53 short hairpin RNA
(shRNA) vector and its human Rb shRNA control vector were
kindly provided by Dr. SW. Lowe (Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY, USA).
Retroviral infection procedures were done using Phoenix
producing cells as previously described [61].
Quantative Real Time PCR
Total RNA was isolated using the RNAeasy kit (Qiagen) according
to the manufacturer’s protocol. A 2 mga l i q u o to ft h et o t a lR N Aw a s
reverse transcribed using MMLV RT (Promega) and random
hexamer primers. QRT-PCR was performed using SYBR Green
PCR Master Mix (Applied Biosystems) on ABI 7000 instrument
(Applied Biosystems). The values for the specific genes were
normalized either to GAPDH or to HPRT housekeeping control.
Specific primers were designed to the following genes: mouse HPRT:
sense, GCAGTACAGCCCCAAAATGG; antisense, GGTCCTT-
TTCACCAGCAAGCT; mouse osterix: sense, CCTCTGCG-
GGACTCAACAAC; antisense, AAAGGTCAGCGTATGGCT-
TCTT; mouse Runx2: sense, AGGCACAGACAGAAGCTT-
GATG, antisense, GCGATCAGAGAACAAACTAGGTTTAGA;
mouse osteocalcin: sense, GACCGCCTACAAACGCATCT, anti-
sense, GGGCAGCACAGGTCCTAAATAGT; mouse PPARc:
TCAGGCTTCCACTATGGAGTTCA, antisense, GAAAAA-
ACCCTTGCATCCTTCA; mouse CEBPa: sense, CGGGCAA-
AGCCAAGAAGTC, antisense, CGTACCCGGTACTCGT-
TGCT; mouse Ap2: sense, TGGAAAGTCGACCACAATAAA-
GAG, antisense, CACCACCAGCTTGTCACCAT, mouse Adi-
poQ: sense, GGATCTGACGACACCAAAAGG, antisense AG-
GAGAGCTTGCAACAGTAGCAT; mouse Pax3: sense, TGAG-
CGAGCCTCTGCACC, antisense, TCAGAGTCAATATCG-
GAGCCT; mouse Pax7: sense, AGCTGCTGTTGATTACCT-
GGC, antisense, CATACGGCGCTGTGTGGA, mouse Myf5:
sense,ACAGCAGCTTTGACAGCATCTACT,antisense,GCAG-
CACATGCATTTGATACATC, mouse MyoD: sense, GTTCT-
TCACGCCCAAAAGATG, antisense, GGACAGTTGGGAA-
GAGTGTCATT; mouse Myogenin: sense, GTCCCAACCCAG-
GAGATCATT, antisense, GCAGATTGTGGGCGTCTGTAG;
mouseNkx2.5: sense, CCTCGGGCGGATAAAAAAGA, antisense,
GGCTTTGTCCAGCTCCACTG; mouse Isl: sense, CGCC-
TTGCAAAGCGACATA, antisense, AAATTGACCAGTTGCT-
GAAAAGC; mouse GATA4: sense, CACCCCAATCTCGA-
TATGTTTGAT, antisense, TGACACACTCTCTGCCTTCT-
GAG; mouse GATA6: sense, GGCCGTTCTTCTCGCACAT,
antisense, CTACTCCAACCTGACTTTTGATTCC mouse
Myocd: sense, TTACAGTTACGGCTTCAACAGAGAA, anti-
sense, GCGGTATTAAGCCTTGGTTAGC; mouse CNN1: sense,
ATGGCCAAGACAAAAGGAAACA, antisense, CTCTGCA-
TACTTGACTCCCACATT; mouse aSMA: sense, ACATCAGG-
GAGTAATGGTTGGAAT, antisense, TCCCCCACATAGCT-
GTCTTTTT; mouse p53: sense, CACGTACTCTCCTCCCCT-
CAAT, antisense, AACTGCACAGGGCACGTCTT; human
GAPDH: sense, AGCCTCAAGATCATCAGCAATG, antisense,
CACGATACCAAAGTTGTCATGGAT; human Myocd: sense,
CGAGTCTGATCCGGAGAAAGC, antisense, CTGTGAAAGA-
GGCCATAAAAGGTAA; human CNN1: sense, CCGTGAA-
GAAGATCAATGAGTCAA, antisense, CAGGTCGTTGGCCT-
CAAAA; human aSMA: sense, TCTAAGGCCGGCTTTGCT,
antisense, CGTAGCTGTCTTTTTGTCCCATT; human SM-
MHC: sense, GGATTGTGCAGACACTGAGTTTTTA, anti-
sense, GACCGGTTACCGTGGATATGTT. The results are
presented as a mean6SD of two duplicate runs from a representative
experiment.
Western blot analysis
For Western blotting, total cell extracts were prepared, 50 mg
protein of each sample was fractionated by gel electrophoresis, and
transferred to nitrocellulose membranes. The following primary
antibodies were used: rabbit polyclonal anti-p53 (1:1000, pro-
duced in our laboratory), rabbit polyclonal anti-p21 (1:1000, C-19;
Santa Cruz Biotechnology, Santa Cruz, CA), mouse monoclonal
anti a-SMA (1:1000, Sigma, IL), mouse monoclonal anti SM-
MHC (1:500, Sigma, IL), mouse monoclonal anti-GAPDH
(MAB374; Chemicon International, Chandlers Ford, United
Kingdom). Horseradish peroxidase anti-mouse and anti-rabbit
(Sigma, IL) were used as secondary antibodies. The signal was
detected by the super-signal-enhanced chemiluminescence system
(Pierce).
Supporting Information
Figure S1 p53 inhibits the adipogenic differentiation program in
the MBA-15 cell line. (A and B) Confluent cultures of MBA-15-sh-
p53 and control cells were subjected to induction of adipogenic
differentiation by treatment with medium containing 10 mg/ml
insulin, 10-6M dexamethasone, 0.5 Mm 3-Isobutyl-1-methylxan-
thine (Adipogenic medium) or with control medium (non treated,
NT). The cells were grown for three weeks with medium
replacement once in three days. Total RNA was isolated before
to the induction of differentiation (od) as well as 7 and 21 days
later. Relative expression of PPARc, CEBPa, Ap2 and AdipoQ
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PCR are presented as a range of two duplicate runs (N=2) after
normalization to HPRT control. (A) Adipogenic differentiation
was assessed using Oil Red O staining for lipid droplets (B).
Found at: doi:10.1371/journal.pone.0003707.s001 (1.57 MB TIF)
Figure S2 Cells expressing a dominant negative p53 protein
display enhanced myofibroblast/smooth muscle differentiation. h-
TERT immortalized, early passaged WI-38 cells stably expressing
GSE56 (GSE56) or control empty vector (Neo) were grown in
culture for 48 hours (non treated, NT); serum starved for
24 hours, and then treated with a fresh serum-free medium with
1 ng/ml TGFb for 24 h. Relative expression of aSMA, CNN1
and SM-MHC was determined by QRT-PCR. The results of
QRT-PCR are presented as a range of two duplicate runs (N=2)
after normalization to GAPDH control.
Found at: doi:10.1371/journal.pone.0003707.s002 (0.09 MB TIF)
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